Testing MQ710 injections alone or with pembrolizumab for advanced cancers
Treatments studied
Part of Cancer, Infections, Skin clinical trials.
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- You have advanced or metastatic cancer that has come back or did not respond to usual treatments, or there is no standard option
- You have at least 2 spots the team can inject/target (skin, under the skin, or lymph nodes), and they can biopsy one spot
- You can have a screening biopsy (and, if needed, a surgical biopsy approach) and you agree to it
- Your general health and organ tests are good enough (blood counts, kidneys, liver, and ability to tolerate treatment)
- You have had limited recent treatment, and you meet specific timing rules for prior therapies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This study tests a new drug (TQB2916) combined with chemotherapy or another drug (penpulimab) in people with certain advanced soft tissue sarcomas or melanoma. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new drug, TQB2922, for people with advanced cancers that have not responded to standard treatments. The goal is to see if it is safe and how it affects the cancer.
This study tests an experimental drug called TQB2252 for people with advanced cancer that has not improved with standard treatments. The drug aims to boost your immune system to fight the cancer more effectively.
This study tests an investigational drug called TQB6426 for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called GPC3 found on some tumor cells. The goal is to see if the drug is safe and effective.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
Hear when a new Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.